PriceTargets.com logo

NASDAQ:AGLE - Aeglea BioTherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 700.00 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.50 As of 05/25/2022 01:00 AM ET
▲ +0.13 (9.49%)

This chart shows the closing price for AGLE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aeglea BioTherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGLE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGLE

Analyst Price Target is $12.00
▲ +700.00% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Aeglea BioTherapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 700.00% upside from the last price of $1.50.

This chart shows the closing price for AGLE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Aeglea BioTherapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2022Piper SandlerLower Price TargetOverweight$7.00 ➝ $4.00Low
5/6/2022Piper SandlerLower Price Target$9.00 ➝ $7.00Low
5/5/2022HC WainwrightLower Price Target$20.00 ➝ $17.00Low
12/6/2021Piper SandlerLower Price TargetOverweight ➝ Overweight$12.00 ➝ $9.00High
11/5/2021Lifesci CapitalReiterated RatingOutperformLow
8/6/2021Evercore ISIInitiated CoverageBuy$20.00Medium
6/24/2021Needham & Company LLCReiterated RatingBuy$12.00High
11/9/2020HC WainwrightReiterated RatingBuy$17.00 ➝ $15.00High
10/23/2020Lifesci CapitalReiterated RatingOutperformMedium
9/16/2020HC WainwrightReiterated RatingBuy$17.00Medium
8/10/2020Needham & Company LLCReiterated RatingBuy$11.00High
5/26/2020Needham & Company LLCInitiated CoverageBuy$11.00Low
5/8/2020HC WainwrightLower Price TargetBuy$18.00 ➝ $17.00Low
5/7/2020Needham & Company LLCLower Price TargetBuy$14.00 ➝ $11.00High
5/4/2020Piper SandlerInitiated CoverageOverweight$12.00Medium
4/30/2020HC WainwrightLower Price TargetBuy$24.00 ➝ $18.00Low
4/8/2020Needham & Company LLCReiterated RatingBuy$14.00High
2/26/2020Needham & Company LLCReiterated RatingBuy ➝ Average$14.00High
2/25/2020HC WainwrightBoost Price TargetBuy$20.00 ➝ $24.00High
6/3/2019HC WainwrightReiterated RatingBuy$20.00Low
5/21/2019HC WainwrightInitiated CoverageBuy$20.00 ➝ $20.00High
3/21/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$14.00Medium
9/4/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
6/14/2018BMO Capital MarketsInitiated CoverageOutperform$21.00High
4/24/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$37.00High
4/13/2018Needham & Company LLCBoost Price TargetBuy$20.00High
3/14/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$8.00 ➝ $12.00High
3/14/2018BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$18.00Medium
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/27/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/25/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/26/2022

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Aeglea BioTherapeutics logo
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $1.50
Low: $1.33
High: $1.51

50 Day Range

MA: $1.94
Low: $1.31
High: $2.72

52 Week Range

Now: $1.50
Low: $1.29
High: $8.50

Volume

211,204 shs

Average Volume

481,957 shs

Market Capitalization

$75.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Aeglea BioTherapeutics?

The following sell-side analysts have issued reports on Aeglea BioTherapeutics in the last year: Evercore ISI, HC Wainwright, Lifesci Capital, Needham & Company LLC, Piper Sandler, StockNews.com, and Zacks Investment Research.
View the latest analyst ratings for AGLE.

What is the current price target for Aeglea BioTherapeutics?

0 Wall Street analysts have set twelve-month price targets for Aeglea BioTherapeutics in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 700.0%.
View the latest price targets for AGLE.

What is the current consensus analyst rating for Aeglea BioTherapeutics?

Aeglea BioTherapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AGLE will outperform the market and that investors should add to their positions of Aeglea BioTherapeutics.
View the latest ratings for AGLE.

How do I contact Aeglea BioTherapeutics' investor relations team?

Aeglea BioTherapeutics' physical mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company's listed phone number is (512) 942-2935 and its investor relations email address is [email protected] The official website for Aeglea BioTherapeutics is www.aegleabio.com. Learn More about contacing Aeglea BioTherapeutics investor relations.